Meeting
2017 ASCO Annual Meeting
Outcomes with lower intensity therapy in TP53-mutated AML.
Authors
Tapan M. Kadia
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
Tapan M. Kadia , Prajwal C. Boddu , Farhad Ravandi , Guillermo Garcia-Manero , Gautam Borthakur , Michael Andreeff , Elias Jabbour , Courtney Denton Dinardo , Marina Konopleva , Naval Guastad Daver , Koichi Takahashi , Keyur Patel , Rashmi Kanagal-Shamanna , Jorge E. Cortes , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7017)
DOI
10.1200/JCO.2017.35.15_suppl.7017
Abstract #
7017
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
First Author: Eric Huselton
Poster
2022 ASCO Annual Meeting
Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
First Author: Farhad Ravandi
Poster
2020 ASCO Quality Care Symposium
Healthcare resource utilization and total cost of care in older patients with acute myeloid leukemia ineligible for intensive chemotherapy.
First Author: Thomas William LeBlanc
Poster
2018 ASCO Annual Meeting
Outcomes of patients with nucleoplasmin 1 (NPM1) mutated acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs).
First Author: Mahesh Swaminathan